235 related articles for article (PubMed ID: 10813290)
21. Cancer in association with polymyalgia rheumatica and temporal arteritis.
Haga HJ; Eide GE; Brun J; Johansen A; Langmark F
J Rheumatol; 1993 Aug; 20(8):1335-9. PubMed ID: 8230015
[TBL] [Abstract][Full Text] [Related]
22. [Giant cell arteritis and polymyalgia rheumatica presenting as subclavian artery obstruction].
Sato M; Takeda A; Hagiwara S; Mochizuki M; Minato N; Saito K; Kano S
Ryumachi; 1993 Aug; 33(4):330-4. PubMed ID: 8235915
[TBL] [Abstract][Full Text] [Related]
23. Lack of consistent peripheral blood lymphocyte transformation responses in polymyalgia rheumatica and giant cell arteritis.
Jones JG; Park JR; Hazelman BL; Ward M; Bulgen DY
J Rheumatol; 1980; 7(6):891-4. PubMed ID: 7205827
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis.
Myklebust G; Gran JT
Br J Rheumatol; 1996 Nov; 35(11):1161-8. PubMed ID: 8948307
[TBL] [Abstract][Full Text] [Related]
25. Giant-cell arteritis in the southern United States. An 11-year retrospective study from the Texas Gulf Coast.
Gonzalez EB; Varner WT; Lisse JR; Daniels JC; Hokanson JA
Arch Intern Med; 1989 Jul; 149(7):1561-5. PubMed ID: 2742429
[TBL] [Abstract][Full Text] [Related]
26. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.
De Miguel E; Karalilova R; Macchioni P; Ponte C; Conticini E; Cowley S; Tomelleri A; Monti S; Monjo I; Batalov Z; Klinowski G; Falsetti P; Kane DJ; Campochiaro C; Hočevar A
Ann Rheum Dis; 2024 Feb; 83(3):335-341. PubMed ID: 37932008
[TBL] [Abstract][Full Text] [Related]
27. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.
Roche NE; Fulbright JW; Wagner AD; Hunder GG; Goronzy JJ; Weyand CM
Arthritis Rheum; 1993 Sep; 36(9):1286-94. PubMed ID: 8216422
[TBL] [Abstract][Full Text] [Related]
28. C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients.
Boiardi L; Farnetti E; Macchioni P; Nicoli D; Croci S; Muratore F; Marvisi C; Ricordi C; Catanoso M; Galli E; Salvarani C
Clin Exp Rheumatol; 2024 Apr; 42(4):803-810. PubMed ID: 37534674
[TBL] [Abstract][Full Text] [Related]
29. HLA antigens in patients with giant cell arteritis and polymyalgia rheumatica.
Hunder GG; Taswell HF; Pineda AA; Elveback LR
J Rheumatol; 1977; 4(3):321-3. PubMed ID: 926109
[TBL] [Abstract][Full Text] [Related]
30. A genetic approach to the aetiology of giant cell arteritis: depletion of the CD8+ T-lymphocyte subset in relatives of patients with polymyalgia rheumatica and arteritis temporalis.
Johansen M; Elling P; Elling H; Olsson A
Clin Exp Rheumatol; 1995; 13(6):745-8. PubMed ID: 8835249
[TBL] [Abstract][Full Text] [Related]
31. Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis.
Armstrong RD; Behn A; Myles A; Panayi GS; Welsh KI
J Rheumatol; 1983 Aug; 10(4):659-61. PubMed ID: 6413689
[TBL] [Abstract][Full Text] [Related]
32. Polymyalgia rheumatica and giant cell arteritis.
Cimmino MA; Salvarani C
Baillieres Clin Rheumatol; 1995 Aug; 9(3):515-27. PubMed ID: 7497536
[TBL] [Abstract][Full Text] [Related]
33. HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome.
Richardson JE; Gladman DD; Fam A; Keystone EC
Arthritis Rheum; 1987 Nov; 30(11):1293-7. PubMed ID: 3500727
[TBL] [Abstract][Full Text] [Related]
34. Decreased level of suppressor/cytotoxic T cells (OKT8+) in polymyalgia rheumatica and temporal arteritis: relation to disease activity.
Elling H; Elling P
J Rheumatol; 1985 Apr; 12(2):306-9. PubMed ID: 3162021
[TBL] [Abstract][Full Text] [Related]
35. Giant cell arteritis and polymyalgia rheumatica: clues to early diagnosis.
Dwolatzky T; Sonnenblick M; Nesher G
Geriatrics; 1997 Jun; 52(6):38-40, 43-4. PubMed ID: 9194789
[TBL] [Abstract][Full Text] [Related]
36. CD8+ T lymphocyte subset in giant cell arteritis and related disorders.
Elling P; Olsson A; Elling H
J Rheumatol; 1990 Feb; 17(2):225-7. PubMed ID: 2138673
[TBL] [Abstract][Full Text] [Related]
37. The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis.
Arnold MH; Corrigall VM; Pitzalis C; Panayi GS
Clin Exp Rheumatol; 1993; 11(6):629-34. PubMed ID: 8299254
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of self-reported diagnoses of polymyalgia rheumatica and giant cell arteritis in the French prospective E3N- EPIC cohort: A validation study.
Barde F; Ascione S; Pacoureau L; Macdonald C; Salliot C; Boutron-Ruault MC; Seror R; Nguyen Y
Semin Arthritis Rheum; 2024 Feb; 64():152298. PubMed ID: 38000317
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin (Gm) allotype frequencies in patients with giant bell arteritis and polymyalgia rheumatica.
Demaine AG; Vaughan RW; Behn AR; Myles AB; Panayi GS; Welsh KI
J Immunogenet; 1983 Oct; 10(5):343-8. PubMed ID: 6644068
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica.
De Miguel E; Macchioni P; Conticini E; Campochiaro C; Karalilova R; Monti S; Ponte C; Klinowski G; Monjo-Henry I; Falsetti P; Batalov Z; Tomelleri A; Hocevar A
Rheumatology (Oxford); 2024 Jan; 63(1):158-164. PubMed ID: 37129541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
